$573.3 million commitment to PBS medication from Australian Governement

Women’s health & the Endometriosis community changes in Australia. 

Small steps from awareness will get us toward a better future. 

On March 16th 2025, the Australian Government announced changes aimed at improving women’s health and supporting the Endometriosis community. These updates include making certain contraceptive pills, Endometriosis treatments and IVF procedures more affordable by adding them to the Pharmaceutical Benefits Scheme (PBS).

This investment is part of a $573.3 million commitment to women’s health, providing more choices, reducing costs and improving care. While it’s not a cure or an overnight solution, it is a positive step forward.

Key PBS additions & their impact:

Slinda® (Progestogen-only pill)

• Available on the PBS from May 1st

• Helps over 100,000 women who cannot take estrogen based contraceptives

• Without the subsidy, it could cost $250+ per year

Ryeqo® (Endometriosis treatment option)

• Available on the PBS from May 1st

• Designed to relieve moderate to severe endometriosis pain

• Without the subsidy, it could cost $2,700+ per year

Pergoveris® (IVF treatment)

• Available earlier in IVF cycles from April 1st

• Reduces costs from $3,500+ to a single co payment

Why this matters?

For those living with Endometriosis, infertility challenges or the need for specialized contraception, the financial burden of treatments can be overwhelming. The PBS listing of these medications means that more people will have access to essential treatments without the excessive out of pocket expenses.

This step forward in healthcare policy is a reminder that change is possible and with continued advocacy, even more progress can be made for women’s health and the Endometriosis community.

Source: health.gov.au